Don't try to scare people here. An RS is not a requirement for appeal. Cytrx have gotten extension without RS. They may not delist solely on one compliant issue of being under 1$. They can still get an extension if other NASDAQ requirements are good. They just have to present a plan or a case that makes NASDAQ believe they will gain compliant again in 180 days.
So no, there is no such thing as a mandatory RS proposal.